Cardinal Health reported strong fiscal 2026 results, with revenue reaching USD 254.2 billion, representing a 14 percent year-over-year increase. The company also demonstrated significant improvements in profitability and cash generation, with GAAP diluted EPS rising 12 percent to USD 7.23 and operating cash flow surging 116 percent to USD 5.2 billion. Non-GAAP metrics further highlighted this strength, with adjusted diluted EPS climbing 33 percent to USD 10.95.
Looking ahead, Cardinal Health provided optimistic guidance for fiscal 2027, projecting adjusted EPS growth between 13 percent and 15 percent. This outlook exceeds the company's long-range target range of 12 percent to 14 percent, driven by robust performance in its specialty segment, which surpassed USD 50 billion in revenue. The company expects acquisitions to contribute an additional 2 to 3 percent to profit growth in the coming fiscal year.
Analyst sentiment remains positive, with a consensus rating of Moderate Buy and an average 12-month price target of USD 266.56, suggesting significant upside potential from the current trading price. While management emphasizes a lean operating model running at approximately 1 percent margin, the combination of strong earnings beats and elevated guidance reinforces the investment case for the healthcare distributor.
📈 Fiscal 2026 revenue surged 14% to USD 254.2 billion.
Cardinal Health stock closed at USD 220.22 on September 25, 2026, trading down 1.08 percent from the previous session. The company operates a modern pharmaceutical distribution facility in Dublin, Ohio, and maintains its listing on the New York Stock Exchange.
At the Morgan Stanley 24th Annual Global Healthcare Conference held on September 14, 2026, Cardinal Health management outlined its fiscal outlook. They described fiscal 2027 growth as a continuation of fiscal 2026's performance but at more normalized rates following an unusually strong pace in the prior year.
Management highlighted that all five operating segments delivered strong performance during fiscal 2026. While pharmaceutical distribution remains central to the business, the company identified specialty care, BioPharma Solutions, at-home care, nuclear medicine, and logistics as key growth areas for future investment.
Regarding specific segment outlooks, management noted that specialty growth is expected to moderate from the high levels reported in fiscal 2026. Despite this moderation, the company maintains that specialty remains a primary focus for strategic investment and expansion.
📉 CAH stock down 1.08% at USD 220.22 on Sept 25, 2026.
✅ All five segments delivered strong performance during fiscal 2026.
💊 Pharmaceutical distribution remains the central pillar of business model.
🚀 Specialty care and BioPharma Solutions identified as key growth areas.
⚠️ Specialty segment growth expected to moderate from fiscal 2026 pace.
📉 Cardinal Health stock was down 1.08 percent, trading at USD 220.22 on September 25, 2026.
🗓️ Management presented fiscal 2027 guidance as a continuation of fiscal 2026 performance at normalized growth rates.
✅ All five operating segments delivered strong performance during fiscal 2026 according to conference transcripts.
💊 Pharmaceutical distribution remains the central pillar of Cardinal Health's business model.
🚀 Specialty care, BioPharma Solutions, at-home care, nuclear medicine, and logistics are identified as key growth areas.
⚠️ Specialty segment growth is expected to moderate from the unusually strong pace seen in fiscal 2026.
🏭 Cardinal Health operates a modern pharmaceutical distribution facility located in Dublin, Ohio.
Bullish Signals
All five segments delivered strong performance in fiscal 2026.
Management prioritizes specialty care investment despite growth moderation.
Company expands footprint in BioPharma Solutions and logistics.
Risk Factors
Specialty segment growth moderates from strong fiscal 2026 pace.
Fiscal 2027 growth projected at normalized rates vs fiscal 2026.
Bullish Signals
All five operating segments delivered strong performance during fiscal 2026.
Management maintains that specialty care remains a key focus for investment despite expected growth moderation.
The company continues to expand its footprint in BioPharma Solutions, at-home care, nuclear medicine, and logistics.
Risk Factors
Specialty segment growth is expected to moderate from the unusually strong pace reported for fiscal 2026.
Fiscal 2027 growth is projected at more normalized rates compared to the exceptional performance of fiscal 2026.
Cardinal Health (CAH) and McKesson (MCK) are competing in U.S. pharmaceutical distribution, with CAH showing stronger recent earnings momentum despite underperforming the broader medical sector over the past six months. In fiscal Q4 2026, Cardinal Health reported a 6% revenue increase to $63.7 billion, a 16% rise in gross profit, and a significant 30% jump in operating income, driven primarily by its Pharmaceutical and Specialty Solutions segment.
The company is executing a strategic shift toward a diversified, specialty-led model with growth in its Other businesses, which saw 7% revenue and 14% profit growth in the same quarter. Key initiatives include expanding MSO capabilities through the Specialty Alliance, integrating Solaris to deepen physician relationships, and leveraging theranostics expansion within Nuclear and Precision Health while investing in automation and supply-chain technology.
Looking ahead to fiscal Q1 2027, analysts project CAH sales of $66.96 billion (up 4.6%) and EPS of $2.92 (up 14.5%), with stable earnings estimates over the past week. The stock trades at a P/E multiple of 17.2, offering a moderate valuation backdrop below the sector average but above its five-year median, supported by strong projected EPS growth and favorable Zacks Style Scores in Value and Momentum.
📈 Q4 2026 operating income jumped 30% driven by Pharmaceutical and Specialty Solutions.
🚀 Other businesses delivered 7% revenue growth and 14% profit growth.
💊 Expanding MSO capabilities via Specialty Alliance and Solaris integration strengthens specialty care.
🔬 Nuclear and Precision Health segments benefit from theranostics expansion and automation investments.
📊 Analysts project Q1 2027 sales of $66.96B and EPS of $2.92, a 14.5% increase.
📈 Cardinal Health reported a 30% jump in operating income and 16% increase in gross profit for fiscal Q4 2026, driven by its Pharmaceutical and Specialty Solutions anchor.
🚀 The company's Other businesses generated 7% revenue growth and 14% profit growth, highlighting diversification beyond traditional distribution.
💊 CAH is expanding its MSO capabilities through the Specialty Alliance and integrating Solaris to strengthen relationships in specialty care.
🔬 Nuclear and Precision Health segments are benefiting from theranostics expansion and investments in automation technology.
📊 Analysts project fiscal Q1 2027 sales of $66.96 billion and EPS of $2.92, representing a 14.5% increase in earnings per share.
💰 Cardinal Health trades at a P/E multiple of 17.2, which is below the Zacks Medical sector average but above its five-year median.
📉 The stock has gained 4.7% over the past six months, outperforming McKesson's 0.1% increase despite lagging the S&P 500.
🏆 CAH holds a Zacks Value Score of A and Momentum Score of A, contrasting with McKesson's lower scores in these categories.
⚠️ Key risks for Cardinal Health include tariff uncertainty, regulatory changes, and the execution of its GMPD improvement plan.
Bullish Signals
Operating income jumped 30% in Q4 2026.
Gross profit rose 16% driven by strong performance.
Other businesses saw 7% revenue and 14% profit growth.
Analysts project Q1 2027 EPS of $2.92 (+14.5%).
Stock gained 4.7% in six months, outperforming McKesson.
Risk Factors
Underperformed sector +9.1% and S&P 500 +17.7% in six months.
Cardinal Health reported a 30% jump in operating income and 16% increase in gross profit for fiscal Q4 2026, driven by strong performance in Pharmaceutical and Specialty Solutions.
The company's Other businesses generated 7% revenue growth and 14% profit growth, demonstrating successful diversification beyond traditional distribution models.
Analysts project fiscal Q1 2027 EPS of $2.92, representing a robust 14.5% increase compared to the prior year.
Cardinal Health trades at a P/E multiple of 17.2, offering a moderate valuation below the sector average while maintaining strong projected earnings growth.
The stock has gained 4.7% over the past six months, outperforming its primary competitor McKesson during the same period.
Risk Factors
Cardinal Health underperformed the Zacks Medical sector's rise of 9.1% and the S&P 500's return of 17.7% over the past six months.
Key risks for the company include ongoing tariff uncertainty, regulatory changes, and the execution challenges associated with its GMPD improvement plan.
Cardinal Health (CAH) shares closed down 1.64% at $222.04, continuing a broader decline for the stock over the past month which saw a 2.85% drop. This underperformance occurred while the wider Medical sector fell 3.65%, contrasting with gains in the Nasdaq and S&P 500.
Analysts are closely monitoring Cardinal Health ahead of its upcoming earnings disclosure, with consensus estimates projecting an EPS of $2.92, representing a 14.51% increase from the prior-year quarter. Revenue is expected to reach $66.96 billion, up 4.6% year-over-year.
Full-year projections indicate earnings of $12.55 per share and revenue of $266.02 billion, reflecting anticipated growth rates of +11.46% and +4.63% respectively from the prior year. The company currently holds a Zacks Rank #3 (Hold) with no recent changes to consensus EPS estimates.
📉 Cardinal Health shares fell 1.64% to $222.04, extending a monthly decline.
📈 Analysts forecast quarterly EPS of $2.92, up 14.51% year-over-year.
💰 Revenue is projected at $66.96 billion for the quarter, up 4.6%.
🏆 Zacks Rank remains #3 (Hold) with no changes to consensus estimates.
💵 Forward P/E of 17.99 sits slightly above the industry average of 16.97.
📉 Cardinal Health shares closed down 1.64% at $222.04, extending a monthly decline of 2.85%.
📈 Analysts expect quarterly EPS of $2.92, marking a 14.51% increase from the prior-year quarter.
💰 Revenue is forecasted to reach $66.96 billion for the quarter, up 4.6% year-over-year.
📅 Full-year earnings are projected at $12.55 per share with revenue of $266.02 billion.
🏆 The company maintains a Zacks Rank #3 (Hold) with no recent changes to consensus estimates.
💵 Cardinal Health trades at a Forward P/E ratio of 17.99, slightly above the industry average of 16.97.
📊 The stock has a PEG ratio of 1.36 compared to an industry average of 1.91 for Medical - Dental Supplies stocks.
Bullish Signals
Analysts project quarterly EPS of $2.92, a 14.51% increase.
Full-year earnings expected to grow 11.46% to $12.55.
Risk Factors
Shares down 2.85% over past month.
Trades at premium Forward P/E of 17.99.
Bullish Signals
Analysts project quarterly EPS of $2.92, representing a significant 14.51% increase from the prior-year quarter.
Full-year earnings are expected to grow by 11.46% to $12.55 per share, indicating strong long-term growth expectations.
Risk Factors
Shares closed down 1.64% today and have lost 2.85% over the past month, trailing the broader Medical sector decline.
The stock trades at a Forward P/E ratio of 17.99, which represents a premium valuation compared to the industry average of 16.97.
Cardinal Health shares closed at $224.95 on September 18, 2026, trading roughly 18.5% below the consensus analyst price target of $266.56. The company reported a strong fiscal 2026 performance driven by double-digit earnings growth across all five operating segments, supported by exceptional specialty growth, customer onboarding, acquisitions, and solid healthcare utilization.
Management has set an ambitious medium-term goal of adjusted EPS growth between 13% and 15% per year starting from fiscal 2026. This trajectory is underpinned by the company's diversified portfolio of healthcare services and products. Analyst sentiment remains constructive with a 'Moderate Buy' rating based on 16 buy ratings versus 3 hold ratings, reflecting confidence in the company's earnings expansion capabilities.
The stock currently trades at a trailing price-to-earnings ratio of 31.11, indicating a valuation that reflects growth expectations rather than deep value characteristics. With a market capitalization of $52.32 billion, Cardinal Health is positioned for potential capital gains tied to its EPS growth targets, though the dividend yield remains modest at 0.92% compared to some healthcare peers.
📈 Stock closed at $224.95 with 18.5% upside to analyst target of $266.56.
🚀 Achieved double-digit earnings growth across all five operating segments in fiscal 2026.
🎯 Management targets adjusted EPS growth of 13% to 15% annually starting fiscal 2026.
📊 Analyst consensus is 'Moderate Buy' with 16 buy and 3 hold ratings.
⚠️ Growth normalization risk as one-off specialty boosts are expected to moderate in 2027.
📈 Cardinal Health stock closed at $224.95 on September 18, 2026, leaving approximately 18.5% upside to the average analyst price target of $266.56.
🚀 The company achieved double-digit earnings growth in all five operating segments during fiscal 2026, driven by specialty growth and acquisitions.
🎯 Management targets adjusted EPS growth of 13% to 15% per year starting from fiscal 2026, supported by a diversified healthcare portfolio.
📊 Analyst sentiment is constructive with a consensus rating of 'Moderate Buy' based on 16 buy ratings and 3 hold ratings as of September 19, 2026.
💰 The stock trades at a trailing P/E ratio of 31.11, reflecting growth expectations within a wide 52-week trading range between $145.87 and $258.30.
⚠️ Growth normalization is a key risk as fiscal 2026 benefits from one-off boosts like exceptional specialty growth that are expected to moderate in fiscal 2027.
Bullish Signals
Double-digit earnings growth across all five segments in fiscal 2026.
Risk Factors
FY26 earnings boosted by acquisitions expected to normalize in FY27.
Risk: Specialty volumes/synergies falling faster than anticipated.
Bullish Signals
Cardinal Health achieved double-digit earnings growth across all five operating segments in fiscal 2026, providing a strong base for future performance.
The company is targeting adjusted EPS growth of 13% to 15% per year starting from fiscal 2026, supported by its diversified healthcare services and products portfolio.
Analyst sentiment remains constructive with a consensus rating of Moderate Buy, based on an average rating score of 2.84 from 16 buy ratings and 3 hold ratings.
The stock has increased by 9.4% year-to-date to $224.95, trading closer to the upper end of its 52-week range while still below the consensus price target.
Risk Factors
Fiscal 2026 earnings were boosted by unusually strong specialty growth and acquisitions that management expects to moderate in fiscal 2027, introducing a risk of normalization.
If specialty volumes or acquisition-related synergies fall back faster than anticipated, the targeted adjusted EPS growth of 13% to 15% per year could be more difficult to achieve.
On January 13, 2026, Cardinal Health raised its fiscal 2026 non-GAAP diluted earnings per share outlook to at least $10.00, expanding from a previous range of $9.65 to $9.85. The company cited strong performance across all five operating segments and signaled continued operational momentum ahead of a detailed update scheduled for February 5.
Cardinal Health projected that its Specialty revenues would exceed $50 billion in fiscal 2026, representing a three-year compounded annual growth rate of 16%. This growth is underpinned by robust demand in specialty distribution and the expansion of its management services organization platforms. Additionally, the company anticipates more than 30% revenue growth in BioPharma Solutions.
The healthcare distributor highlighted major new patient-support hub wins, including partnerships with Sanofi and Regeneron's Dupixent My Way program. Cardinal Health also reported successfully transitioning manufacturer distribution service agreements for drugs affected by the 2026 Medicare Drug Price Negotiation Program before the January 1 implementation to preserve compensation.
Furthermore, the company launched the ContinuCare Pathway program within its at-Home Solutions business to streamline medical-benefit diabetes supply delivery. This new pharmacy-to-supplier referral model has already been adopted by Publix's nearly 1,400 pharmacies and is expanding to over 11,000 retail and grocery pharmacies.
📈 Raised fiscal 2026 EPS outlook to at least $10.00.
💰 Specialty revenues projected to exceed $50 billion in 2026.
🚀 BioPharma Solutions expected to grow over 30% via new platforms.
🤝 Secured major patient-support hub wins with Sanofi and Regeneron.
⚖️ Successfully transitioned distribution agreements before January 1 Medicare deadline.
📈 Cardinal Health raised its fiscal 2026 non-GAAP diluted EPS outlook to at least $10.00 from a prior range of $9.65 to $9.85.
💰 The company projects Specialty revenues will exceed $50 billion in fiscal 2026, reflecting a 16% three-year compounded annual growth rate.
🚀 BioPharma Solutions is expected to see more than 30% anticipated revenue growth driven by robust demand and new platform expansions.
🤝 Cardinal Health secured major patient-support hub wins with Sanofi and Regeneron's Dupixent My Way program.
⚖️ The company successfully transitioned manufacturer distribution service agreements for drugs affected by the 2026 Medicare Drug Price Negotiation Program before the January 1 deadline.
🏥 Cardinal Health launched the ContinuCare Pathway program to streamline diabetes supply delivery through a pharmacy-to-supplier referral model.
📊 The new pharmacy referral model is already adopted by Publix's nearly 1,400 pharmacies and expanding to over 11,000 retail and grocery locations.
👍 Analysts maintain a Buy rating on CAH stock with a price target of $244.00.
Bullish Signals
Raised fiscal 2026 EPS outlook to at least $10.00.
Specialty revenues projected to exceed $50 billion in FY2026.
BioPharma Solutions revenue anticipated to grow by more than 30%.
Secured major patient-support hub wins with Sanofi and Regeneron.
Successfully transitioned distribution agreements before Medicare negotiation implementation.
Bullish Signals
Cardinal Health raised its fiscal 2026 non-GAAP diluted EPS outlook to at least $10.00, up from a prior range of $9.65 to $9.85.
The company projects Specialty revenues will exceed $50 billion in fiscal 2026, reflecting a three-year compounded annual growth rate of 16%.
BioPharma Solutions is anticipated to grow revenue by more than 30%, driven by robust demand and expansion of management services platforms.
Cardinal Health secured major new patient-support hub wins with Sanofi and Regeneron's Dupixent My Way program.
The company successfully transitioned manufacturer distribution service agreements for drugs affected by the 2026 Medicare Drug Price Negotiation Program before the January 1 implementation.
Cardinal Health launched the ContinuCare Pathway program to streamline diabetes supply delivery, already adopted by Publix's nearly 1,400 pharmacies and expanding to over 11,000 retail and grocery pharmacies.
Jim Cramer highlighted Cardinal Health (CAH) as an 'absolute favorite' on Mad Money, citing its strategic shift from a commoditized distributor to a specialized player with growing exposure to higher-margin healthcare services and specialty pharmaceuticals. The company is outperforming peers like McKesson and Cencora by converting volume into earnings despite lower branded-drug prices driven by Medicare negotiations.
Cardinal Health reported fiscal fourth-quarter revenue of $63.7 billion, a 6% increase that missed estimates but was offset by a $0.31 per share tariff refund benefit. Management forecasts fiscal 2027 non-GAAP EPS growth of 13% to 15%, reaching $12.40 to $12.60, with adjusted free cash flow expected between $3.5 billion and $4 billion. The company is expanding its 'Other' segment, which includes precision health solutions and at-home services, targeting 11% to 13% revenue growth.
Despite the bullish outlook, risks include execution challenges given the stock's rerating near record highs and a forward P/E of 19.01. The company faces potential margin pressure if drug-pricing changes reduce distributor fees or if specialty growth slows. Additionally, customer concentration remains a vulnerability, with CVS Health accounting for 28% of fiscal 2026 revenue and the top five customers representing 43%, exposing earnings to contract losses.
Institutional ownership shows 63 hedge funds holding CAH in the second quarter, down slightly from the first. Cramer argues that in a high-interest-rate environment, Cardinal's credible earnings growth case makes it too attractive to ignore, though investors will need management to deliver on promises after the substantial rerating.
📈 Jim Cramer names CAH an absolute favorite for higher-margin healthcare services transition.
💰 Q4 revenue rose 6% to $63.7B, offset by a $0.31/share tariff refund benefit.
🚀 Management forecasts fiscal 2027 non-GAAP EPS growth of 13% to 15%.
⚠️ Stock near record highs creates valuation risk if specialty growth slows or fees rise.
🏥 'Other' segment expected to deliver 11-13% revenue and 15-18% profit growth in fiscal 2027.
📈 Jim Cramer identifies Cardinal Health as an 'absolute favorite' due to its transition from a commoditized provider to a specialized player with higher-margin healthcare services.
💰 Fiscal Q4 revenue rose 6% to $63.7 billion, though it missed estimates, partially offset by a $0.31 per share tariff refund benefit.
🚀 Management forecasts fiscal 2027 non-GAAP EPS growth of 13% to 15%, targeting $12.40 to $12.60 with adjusted free cash flow of $3.5 billion to $4 billion.
🏥 The 'Other' segment, including precision health and at-home solutions, is expected to deliver 11% to 13% revenue growth and 15% to 18% profit growth in fiscal 2027.
🤝 Cardinal agreed to acquire AdaptHealth's diabetes business and Strive Medical for approximately $360 million to expand at-home medical-supply operations.
⚠️ The stock has rerated close to record highs, creating valuation risk if specialty growth slows or drug-pricing pressures increase distributor fees.
📉 Customer concentration poses a vulnerability, with CVS Health accounting for 28% of fiscal 2026 revenue and the top five customers representing 43%.
💸 Fiscal 2027 adjusted free cash flow projections of $3.5 billion to $4 billion are below the roughly $5 billion generated in fiscal 2026.
📉 Hedge fund ownership decreased slightly to 63 funds in Q2, down from 66 in Q1, while short interest remains low at around 2.7% to 2.8%.
🎯 Cramer believes Cardinal is a 'big winner' in high-interest-rate environments, provided management delivers on its credible earnings growth case.
Bullish Signals
Jim Cramer calls Cardinal Health an 'absolute favorite' due to its successful pivot from commoditized distribution to specialized healthcare services with higher margins.
The company is running circles around competitors like McKesson and Cencora by effectively converting pharmaceutical volume into earnings despite lower drug prices.
Fiscal Q4 revenue grew 6% to $63.7 billion, demonstrating resilience in a challenging pricing environment driven by Medicare negotiations.
Management projects robust fiscal 2027 non-GAAP EPS growth of 13% to 15%, signaling strong confidence in future profitability.
The high-margin 'Other' segment is expected to grow revenue by 11% to 13% and profits by 15% to 18% in fiscal 2027, diversifying the business model.
Strategic acquisitions of AdaptHealth's diabetes business and Strive Medical for $360 million will expand the company's at-home medical-supply footprint.
Risk Factors
The stock has rerated close to its record high, creating significant valuation risk if specialty growth slows or margins fall short of expectations.
Lower branded-drug prices and potential Medicare negotiation impacts can reduce reported sales without a proportional decline in distributor fees, pressuring margins.
Customer concentration is a major vulnerability, with CVS Health alone accounting for 28% of fiscal 2026 revenue and the top five customers representing 43%.
Projected fiscal 2027 adjusted free cash flow of $3.5 billion to $4 billion is below the roughly $5 billion generated in fiscal 2026, raising concerns about cash generation quality.
Jim Cramer highlighted Cardinal Health (CAH) as an 'absolute favorite' on Mad Money, citing its strategic shift from a commoditized distributor to a specialized player with growing exposure to higher-margin healthcare services and specialty pharmaceuticals. The company has outperformed peers like McKesson and Cencora by converting volume into earnings despite headwinds in branded-drug pricing and Medicare negotiations.
Cardinal Health reported fiscal fourth-quarter revenue of $63.7 billion, a 6% increase that missed estimates but was offset by a $0.31 per share tariff refund benefit. Management forecasts fiscal 2027 non-GAAP EPS growth of 13% to 15%, targeting $12.40 to $12.60, while expecting adjusted free cash flow between $3.5 billion and $4 billion. The company is expanding its 'Other' segment, which includes precision health solutions and at-home services, with projected revenue growth of 11% to 13%.
The stock faces risks related to execution and valuation after a substantial rerate near record highs. Key vulnerabilities include customer concentration, where CVS Health accounts for 28% of fiscal 2026 revenue, and the potential for margins to fall short if specialty growth slows or drug-pricing pressures intensify. Additionally, projected fiscal 2027 free cash flow is lower than the roughly $5 billion generated in fiscal 2026, raising questions about capital generation capabilities.
Institutional ownership data shows 63 hedge funds held CAH in the second quarter, down slightly from 66 in the first. Cramer argues that despite these risks and the high forward P/E of 19.01, the company offers a credible case for its valuation given the targeted earnings growth, positioning it as a potential winner in an environment concerned with oil prices and interest rates.
📈 Jim Cramer names Cardinal Health an absolute favorite for its healthcare services transition.
💰 Q4 revenue rose 6% to $63.7B, offset by a $0.31/share tariff refund benefit.
🚀 Management forecasts fiscal 2027 non-GAAP EPS growth of 13% to 15%.
⚠️ Stock near record highs risks valuation reset if specialty growth slows or margins fall.
💸 Projected fiscal 2027 adjusted free cash flow of $3.5B-$4B is below fiscal 2026's $5B.
📈 Jim Cramer identifies Cardinal Health (CAH) as an 'absolute favorite' due to its transition into specialized healthcare services and specialty pharmaceuticals.
💰 Fiscal Q4 revenue rose 6% to $63.7 billion, though it missed estimates, partially offset by a $0.31 per share tariff refund benefit.
🚀 Management forecasts fiscal 2027 non-GAAP EPS growth of 13% to 15%, targeting a range of $12.40 to $12.60.
🏥 The 'Other' segment, including precision health and at-home solutions, is expected to deliver 11% to 13% revenue growth in fiscal 2027.
🤝 Cardinal Health agreed to acquire AdaptHealth's diabetes business and Strive Medical for approximately $360 million to expand at-home operations.
⚠️ The stock has rerated close to record highs, creating a risk of a sharper valuation reset if specialty growth slows or margins fall short.
🏪 Customer concentration remains a vulnerability, with CVS Health accounting for 28% of fiscal 2026 revenue and the top five customers representing 43%.
💸 Projected fiscal 2027 adjusted free cash flow of $3.5 billion to $4 billion is below the roughly $5 billion generated in fiscal 2026.
📉 Hedge fund ownership decreased slightly, with 63 funds holding CAH in Q2 compared to 66 in Q1.
📊 The company trades at a forward P/E of 19.01, requiring management to deliver on growth targets to justify the current valuation.
Bullish Signals
Jim Cramer calls it an 'absolute favorite' for specialized healthcare services pivot.
Risk Factors
Valuation reset risk if growth slows or margins fall short.
CVS Health accounts for 28% of fiscal 2026 revenue.
Management forecasts fiscal 2027 non-GAAP EPS growth of 13% to 15%, projecting a range of $12.40 to $12.60.
The 'Other' segment is expected to produce 11% to 13% revenue growth and 15% to 18% profit growth in fiscal 2027.
Cardinal Health agreed to acquire AdaptHealth's diabetes business and Strive Medical for approximately $360 million to expand its at-home medical-supply operations.
Risk Factors
The stock has rerated close to its record high, creating a risk of a sharper valuation reset if specialty growth slows or margins fall short.
Customer concentration is a significant vulnerability, with CVS Health accounting for 28% of fiscal 2026 revenue and the top five customers representing 43%.
Projected fiscal 2027 adjusted free cash flow of $3.5 billion to $4 billion is below the roughly $5 billion generated in fiscal 2026.
Lower branded-drug prices, including those affected by Medicare negotiations, can reduce reported sales without a proportional decline in distributor fees.
The shift toward generics can have a similar effect because lower-priced drugs generate less revenue but can support attractive margins and high volumes.
Cardinal Health (CAH) shares have surged 420.2% over the past five years, leading Simply Wall St to conclude that the stock is no longer obviously cheap on a broad valuation view. The company currently scores 2 out of 6 on wider valuation checks, indicating it leans expensive rather than representing a clear bargain for investors seeking undervalued opportunities.
The article analyzes Cardinal Health's earnings power using the P/E ratio, noting that CAH trades at 33.7x earnings. This multiple is significantly higher than the broader Healthcare industry average of 25.3x and the peer group average of 27.8x. While a model implies a fair P/E of 32.8x, suggesting the current price roughly matches expectations based on size and risk, the stock does not screen as a clear bargain.
The core investment debate for Cardinal Health centers on whether its strong share price run leaves sufficient potential reward relative to its current valuation. The market appears to have priced in solid execution and stable profitability, meaning future performance must sustain this richer multiple without facing pressure from operating margins or working capital needs.
📈 CAH stock rose 420.2% over the past five years.
💰 CAH trades at a high P/E of 33.7x vs peers.
📊 Simply Wall St rates CAH valuation as expensive (2/6).
⚖️ Fair value P/E model suggests current price matches expectations.
🛑 Investors question if CAH can sustain earnings without margin pressure.
📈 Cardinal Health stock has delivered very strong gains, rising 420.2% over the past five years.
💰 The company trades at a P/E ratio of 33.7x, which is higher than both the Healthcare industry average (25.3x) and peer group average (27.8x).
📊 Simply Wall St valuation checks score Cardinal Health a 2 out of 6, indicating the stock leans expensive rather than being a clear bargain.
⚖️ The model implies a fair P/E ratio of 32.8x, suggesting the current market price roughly matches expectations for the company's size and risk profile.
🛑 Investors face a key question regarding whether Cardinal Health can sustain its earnings power without running into margin or working capital pressure.
📉 The stock does not screen as a clear bargain on earnings multiples, though it is not considered extreme relative to tailored benchmarks.
Bullish Signals
Cardinal Health has delivered very strong gains over the past five years, with shares up 420.2%, indicating robust long-term performance.
The company operates as a healthcare services and products provider in the United States and internationally, maintaining a significant market presence.
Risk Factors
Cardinal Health trades at a P/E ratio of 33.7x, which is substantially higher than the Healthcare industry average of 25.3x and peer group average of 27.8x.
Valuation checks score the stock 2 out of 6, suggesting it leans expensive rather than being a clear bargain for investors.
The current valuation implies that market expectations have already priced in solid execution, leaving limited margin for error regarding operating performance.
Cardinal Health (CAH) reported robust full-year earnings guidance for fiscal 2027 that exceeded analyst expectations, prompting an upgrade in its price target. While Q2 revenue of $63.67 billion missed the $65.03 billion consensus due to regulatory headwinds and lower drug prices, adjusted EPS of $2.60 beat estimates at $2.42. The company's stock rallied over 1% to set a fresh record close, trading near its all-time high despite some profit-taking after hitting intraday peaks.
Analysts highlighted Cardinal Health's enhanced profitability as the firm successfully pivots toward high-margin areas like specialty pharmaceuticals and direct-to-patient delivery. The core Pharmaceutical and Specialty Solutions segment demonstrated strong execution, leveraging a volume-based fee-for-service model to generate superior profits even as Medicare negotiations capped wholesale drug prices. This operational efficiency allowed the company to deliver materially better-than-expected bottom-line results despite top-line pressure.
Looking ahead, Cardinal Health is guiding for 13% to 15% adjusted earnings growth in fiscal 2027, significantly outpacing the Street's $12.04 per share expectation. The 'Other' segment continues to be a key growth driver with double-digit revenue expansion and high profit margins, while free cash flow is projected between $3.5 billion and $4 billion. Consequently, analysts raised their price target to $265 from $245 while maintaining a hold-equivalent rating.
Management emphasized that the company's role in safely delivering life-saving products remains unchanged despite lower wholesale acquisition costs, arguing that compensation should reflect this enduring value. The strategy involves expanding managed services organizations and acquiring businesses to bolster direct-to-patient capabilities, diversifying revenue streams beyond traditional drug distribution. These strategic moves are expected to sustain long-term earnings growth and provide investors with exposure to high-margin healthcare innovations.
📈 Cardinal Health raised price target to $265 after strong EPS beat of $2.60.
📉 Q2 revenue missed estimates due to lower drug prices from Medicare negotiations.
🚀 'Other' segment projected 11% to 13% revenue growth with 10.6% profit margin.
💊 Expanding specialty pharma and direct-to-patient delivery via recent acquisitions.
📈 Cardinal Health raised its price target to $265 from $245 following a strong earnings beat in adjusted EPS of $2.60 versus the $2.42 consensus.
💰 The company delivered robust full-year guidance for fiscal 2027, projecting 13% to 15% adjusted earnings growth well ahead of Wall Street expectations.
📉 Q2 revenue of $63.67 billion missed estimates due to lower drug prices from Medicare negotiations and regulatory changes under the Inflation Reduction Act.
🚀 The 'Other' segment emerged as a high-growth engine with 11% to 13% projected revenue growth and a superior 10.6% segment profit margin.
💊 Cardinal Health is expanding into specialty pharmaceuticals and direct-to-patient delivery, including recent acquisitions to bolster its at-home solutions business.
📉 Free cash flow is expected to reach between $3.5 billion and $4 billion for fiscal 2027, exceeding the consensus estimate of $3.49 billion.
🏥 The Pharmaceutical and Specialty Solutions segment maintained strong profitability despite revenue headwinds from price caps on branded drugs.
📈 Shares of Cardinal Health rose more than 1% to set a fresh record close, reaching near its all-time high of $239.71.
🤝 CEO Jason Hollar affirmed the company's essential role in drug distribution, stating that compensation should not change despite lower wholesale costs.
📊 The 'Other' segment includes Nuclear and Precision Health Solutions and OptiFreight Logistics, driving fast top-line growth with high profitability.
Bullish Signals
Raised price target to $265 on rosy fiscal 2027 profit guidance.
Delivered adjusted EPS of $2.60, beating the $2.42 consensus.
Guiding for 13% to 15% adjusted earnings growth in fiscal 2027.
'Other' segment projected revenue increases of 11% to 13%.
Free cash flow expected between $3.5 billion and $4 billion.
Risk Factors
Q2 revenue missed by $1.36B due to lower drug prices.
'Other' segment revenue slightly short of Wall Street expectations.
Future Pharma profits may drop as contracts renegotiate.
Bullish Signals
Cardinal Health raised its price target to $265 from $245 after issuing rosy profit guidance for fiscal 2027 that significantly beat analyst expectations.
The company delivered an adjusted EPS of $2.60, surpassing the $2.42 consensus estimate, driven by strong execution and increased operating efficiency.
Cardinal Health is guiding for 13% to 15% adjusted earnings growth in fiscal 2027, well ahead of the Street's $12.04 per share expectation.
The 'Other' segment is the fastest-growing unit with projected revenue increases of 11% to 13% and a high 10.6% segment profit margin.
Free cash flow is expected to be between $3.5 billion and $4 billion for fiscal 2027, exceeding the FactSet consensus estimate of $3.49 billion.
The Pharmaceutical and Specialty Solutions segment generated better-than-expected profits despite revenue headwinds from regulatory price caps on drugs.
Cardinal Health is successfully pivoting into high-margin areas like specialty pharmaceuticals and direct-to-patient delivery of healthcare supplies.
Shares of Cardinal Health rose more than 1% to set a fresh record close, demonstrating strong investor confidence in the company's profitability.
Risk Factors
Q2 revenue of $63.67 billion missed expectations of $65.03 billion due to lower drug prices resulting from Medicare negotiations and regulatory changes.
The 'Other' segment revenue of $1.72 billion was slightly short versus Wall Street expectations, though it remains the fastest-growing unit.
Future profits in the Pharmaceutical segment could be impacted as contracts come up for renegotiation under lower wholesale acquisition costs.
Simply Wall St analysis indicates that Cardinal Health (CAH) stock appears overvalued following a strong 334.8% return over the past five years and a 49.3% gain in the last year. The company currently trades at approximately 35.0x earnings, which is significantly higher than the broader healthcare industry average of roughly 26.9x and its peer group average of about 28.1x.
The article argues that the current valuation premium likely prices in optimism regarding Cardinal Health's strategic push into home-based care through planned acquisitions of Strive Medical and AdaptHealth. While management expects these deals to support earnings growth, the stock only passes two of six valuation checks, suggesting it is not a clear bargain based on fundamental metrics.
Investors are now relying more on strong execution than valuation support for future upside. The key question remains whether Cardinal Health can successfully deliver on its home care expansion and integration outcomes to justify the current premium before market sentiment or multiples cool down.
📈 Cardinal Health delivered 334.8% returns over five years.
💰 Stock trades at 35.0x earnings vs 26.9x industry average.
📉 Fair P/E of 29.2x suggests current price includes growth premium.
🏥 Company expanding home care via Strive Medical and AdaptHealth acquisitions.
⚖️ Valuation fails two of six checks, not a clear bargain.
📈 Cardinal Health has delivered a very strong 334.8% return over the past five years and 49.3% in the last year.
💰 The stock currently trades at approximately 35.0x earnings, compared to an industry average of roughly 26.9x and a peer group average of about 28.1x.
📉 The model's fair P/E ratio sits near 29.2x, suggesting the current price includes a premium for future growth expectations.
🏥 Cardinal Health is pursuing growth through planned acquisitions of Strive Medical and AdaptHealth to expand its home-based care portfolio.
⚖️ The stock only passes two of six valuation checks, indicating it does not screen as a clear bargain on broader value tests.
🤔 Investors face the challenge of determining if current share price strength already prices in the expected benefits of the expansion.
🛠️ Success depends on execution and integration outcomes for the home care deals to justify today's premium valuation.
Bullish Signals
334.8% five-year return.
49.3% one-year gain.
Expanding home-care via acquisitions.
Risk Factors
High P/E multiple of 35.0x exceeds industry average of 26.9x.
Valuation premium lacks support from current earnings without deal integration.
Bullish Signals
Cardinal Health has delivered exceptional long-term performance with a 334.8% return over five years and a 49.3% gain in the last year.
The company is executing a strategic expansion into home-based care through planned acquisitions of Strive Medical and AdaptHealth.
Risk Factors
Cardinal Health trades at a P/E multiple of approximately 35.0x, which is significantly higher than the industry average of roughly 26.9x and peer group average of about 28.1x.
The current valuation suggests investors are paying a premium that may not be fully supported by current earnings without successful integration of new deals.
Shares of Cardinal Health, Inc. (NYSE:CAH) have received an average recommendation of 'Moderate Buy' from eighteen brokerages covering the firm, with fifteen analysts rating it a buy and three holding. The consensus one-year price target stands at $251.73. Recent analyst actions include TD Cowen lifting its price target to $275 with a 'buy' rating in July, while Wells Fargo and Evercore recently lowered their targets to $245 and $240 respectively, maintaining positive 'overweight' and 'outperform' ratings.
Cardinal Health reported fourth-quarter earnings on April 30th, delivering $3.17 EPS which significantly beat the consensus estimate of $2.79 by $0.38. Revenue reached $60.94 billion, representing an 11.0% year-over-year increase, though it missed the specific revenue consensus of $62.10 billion. The company has set full-year 2026 guidance between $10.70 and $10.80 EPS, slightly below analyst expectations of $10.77.
The company recently increased its quarterly dividend to $0.5158 per share, paid on July 15th with an ex-dividend date of July 1st, resulting in a 0.9% yield and a 31.50% payout ratio. Significant institutional activity includes Wellington Management Group raising its position by 153.2%, Marshall Wace LLP increasing holdings by over 1,300%, and Norges Bank acquiring a stake valued at approximately $790 million in the fourth quarter.
📊 Consensus target is $251.73 with an 'Moderate Buy' rating.
📈 Q4 EPS beat estimates at $3.17 on $60.94B revenue.
📉 Revenue missed consensus of $62.10B despite 11% growth.
💰 Dividend raised to $0.5158 with a 0.9% yield.
🏦 Wellington Management increased stake by 153.2%.
📊 Cardinal Health holds an average 'Moderate Buy' rating from eighteen brokerages with a consensus one-year price target of $251.73.
📈 The company reported Q4 EPS of $3.17, beating analyst estimates by $0.38 on revenue of $60.94 billion.
📉 Revenue missed the specific consensus estimate of $62.10 billion despite an 11% year-over-year growth rate.
💰 Cardinal Health raised its quarterly dividend to $0.5158, offering a 0.9% yield and a 31.50% payout ratio.
🏦 Wellington Management Group increased its stake by 153.2%, now holding shares valued at over $911 million.
📉 Wells Fargo and Evercore recently lowered their price targets to $245 and $240 respectively, though maintaining positive ratings.
🏛️ Norges Bank acquired a new stake in the fourth quarter valued at approximately $790 million.
🔮 The company has set FY 2026 EPS guidance between $10.70 and $10.80, slightly below analyst expectations of $10.77.
Bullish Signals
EPS beat estimates by $0.38 at $3.17.
Revenue rose 11.0% to $60.94 billion.
TD Cowen upgraded to buy with $275 target.
Wellington Management increased position by 153.2%.
Norges Bank added $790 million stake.
Risk Factors
Revenue of $60.94B missed consensus estimate of $62.10B.
Negative return on equity of -92.61% for the quarter.
Wells Fargo and Evercore reduced price targets to $245 and $240.
Bullish Signals
Cardinal Health beat earnings per share estimates by $0.38 in the latest quarter, reporting $3.17 EPS.
The company achieved an 11.0% year-over-year revenue increase to reach $60.94 billion during the quarter.
TD Cowen lifted its price target to $275 and upgraded the rating to 'buy' in a recent report.
Wellington Management Group significantly increased its position by 153.2% in the third quarter.
Marshall Wace LLP boosted its stake by over 1,300% in the fourth quarter, adding nearly $196 million to holdings.
Norges Bank acquired a substantial new stake valued at approximately $790 million in the fourth quarter.
Vanguard Group Inc. increased its holdings by 2.0% in the fourth quarter, maintaining a large position worth over $6.4 billion.
Risk Factors
Cardinal Health's revenue of $60.94 billion missed the specific consensus estimate of $62.10 billion.
The company reported a negative return on equity of -92.61% for the quarter.
Wells Fargo and Evercore recently reduced their price targets to $245 and $240 respectively.
Florida Financial Advisors LLC increased its holdings in Cardinal Health, Inc. (NYSE:CAH) by 21.0% during the first quarter, purchasing an additional 2,643 shares to reach a total of 15,203 shares valued at $3.21 million. This position represents approximately 0.8% of the firm's portfolio and ranks as its 28th largest holding. Several other institutional investors also adjusted their stakes, with Jones Financial Companies Lllp significantly increasing its position by 198.3% to own 21,112 shares valued at $27,000.
Analyst sentiment regarding Cardinal Health remains mixed but generally positive, with an average target price of $250.07 based on data from MarketBeat.com. While JPMorgan Chase & Co. lowered its price target to $215.00 and maintained a neutral rating, TD Cowen raised its target to $275.00 with a buy rating. Other firms like Wall Street Zen upgraded the stock to a strong-buy, resulting in an average consensus of Moderate Buy among fifteen analysts.
Cardinal Health recently announced a quarterly dividend increase, paying $0.5158 per share to stockholders of record on July 1st, marking a rise from the previous quarterly payout of $0.51. The company currently trades with a market capitalization of $52.88 billion and a P/E ratio of 34.52. As a major provider of healthcare supply chain and distribution services, the firm continues to operate across various service lines supporting hospitals and clinical laboratories.
📈 Florida Financial Advisors added $3.21M CAH shares in Q1.
📊 Jones Financial increased stake by 198.3% to 14,034 shares.
💰 Cardinal Health raised quarterly dividend to $0.5158 per share.
📉 JPMorgan lowered price target to $215 with neutral rating.
📈 TD Cowen raised target to $275 and assigned buy rating.
📈 Florida Financial Advisors LLC grew its CAH holdings by 21.0% in Q1, adding 2,643 shares for a total value of $3.21 million.
📊 Jones Financial Companies Lllp increased its stake by 198.3%, acquiring 14,034 additional shares valued at $27,000.
💰 Cardinal Health raised its quarterly dividend to $0.5158 per share, representing a 0.9% yield and a 31.50% payout ratio.
📉 JPMorgan Chase & Co. decreased its price target from $243.00 to $215.00 with a neutral rating on May 4th.
📈 TD Cowen increased its price target to $275.00 and assigned a buy rating in a July 9th report.
🏆 Wall Street Zen upgraded Cardinal Health from a buy to a strong-buy rating on July 4th.
📊 The stock currently has an average analyst target price of $250.07 with a consensus Moderate Buy rating.
💵 CAH shares opened at $225.76, trading between a one-year low of $137.75 and a high of $243.21.
🏢 Cardinal Health operates as a multinational healthcare services company headquartered in Dublin, Ohio.
📉 Institutional investors collectively own 87.17% of the company's outstanding stock.
Bullish Signals
Florida Financial Advisors increased position by 21.0% in Q1.
Jones Financial expanded stake by 198.3%, adding 14,000 shares.
Quarterly dividend raised to $0.5158 from $0.51.
TD Cowen upgraded target to $275.00 with buy rating.
Wall Street Zen upgraded stock to strong-buy rating.
Risk Factors
JPMorgan lowered price target to $215 with neutral rating.
High P/E ratio of 34.52 compared to peers.
Bullish Signals
Florida Financial Advisors LLC increased its position by 21.0% in Q1, signaling continued institutional interest.
Jones Financial Companies Lllp significantly expanded its stake by 198.3%, adding over 14,000 shares.
The company raised its quarterly dividend to $0.5158 from the previous $0.51, indicating confidence in cash flow.
TD Cowen upgraded the price target to $275.00 with a buy rating, suggesting upside potential.
Wall Street Zen upgraded the stock to a strong-buy rating, reinforcing positive analyst sentiment.
The average analyst target price of $250.07 is above the recent opening price of $225.76.
Risk Factors
JPMorgan Chase & Co. lowered its price target to $215.00 and maintained a neutral rating, indicating caution.
The stock trades at a P/E ratio of 34.52, which may be considered high relative to some peers.
Assetmark Inc. increased its holdings in Cardinal Health, Inc. (NYSE:CAH) by 35.4% during the first quarter, purchasing an additional 27,631 shares to reach a total of 105,770 shares valued at $22.35 million. Several other institutional investors and hedge funds also adjusted their stakes in the company during the fourth and first quarters, with new positions acquired by Aventura Private Wealth LLC, University of Texas Texas AM Investment Management Co., Bank of Jackson Hole Trust, Indiana Trust & Investment Management Co., and Palladiem LLC.
Cardinal Health's stock opened at $228.57 on Friday, trading within a fifty-two-week range of $137.75 to $243.21. The company has a market capitalization of $53.53 billion and a P/E ratio of 34.95. Recently, the firm announced a quarterly dividend of $0.5158 per share, paid on July 15th to investors of record from July 1st, representing an annualized yield of 0.9% and a payout ratio of 31.50%.
Analyst sentiment remains mixed but generally positive regarding the stock's valuation and outlook. Morgan Stanley raised its target price to $255.00 with an 'overweight' rating, while Bank of America increased its objective to $260.00 with a 'buy' rating. Conversely, Zacks Research downgraded the stock from 'strong-buy' to 'hold'. The consensus among fifteen analysts is a 'Moderate Buy' with an average target price of $249.13.
Headquartered in Dublin, Ohio, Cardinal Health operates as a multinational healthcare services and products company established in the early 1970s. It serves hospitals, health systems, pharmacies, physician offices, and clinical laboratories through wholesale distribution of pharmaceuticals, supply of medical-surgical products, and logistics solutions.
📈 Assetmark Inc. increased Cardinal Health holdings by 35.4% in Q1.
💰 New institutional stakes valued between $25,000 and $29,000 were acquired.
📊 Stock trades at a $53.53 billion market cap with a P/E of 34.95.
💵 Quarterly dividend raised to $0.5158 for a 0.9% annualized yield.
🎯 Analyst consensus is 'Moderate Buy' with an average target price of $249.13.
📈 Assetmark Inc. boosted its Cardinal Health holdings by 35.4% in Q1, adding 27,631 shares to a total position of 105,770 shares.
💰 Institutional investors including Aventura Private Wealth LLC and University of Texas Texas AM Investment Management Co. acquired new stakes valued at approximately $25,000-$29,000 each.
📊 Cardinal Health stock trades at a market cap of $53.53 billion with a P/E ratio of 34.95 and a beta of 0.49.
💵 The company paid a quarterly dividend of $0.5158 on July 15th, raising the annualized yield to 0.9% from the previous 0.87%.
📈 Morgan Stanley raised its price target to $255.00 and maintained an 'overweight' rating on the stock.
📉 Zacks Research downgraded Cardinal Health from a 'strong-buy' to a 'hold' rating in late June.
🏥 Cardinal Health provides wholesale distribution of pharmaceuticals and medical-surgical products to healthcare providers.
🎯 Analyst consensus is a 'Moderate Buy' with an average target price of $249.13 based on data from MarketBeat.
Bullish Signals
Assetmark stake rose 35.4% in Q1.
New institutional investors entered positions in Q4 and Q1.
Morgan Stanley raised target to $255.00 with 'overweight' rating.
Bank of America set objective at $260.00 with 'buy' rating.
Dividend increased from $0.51 to $0.5158 per share.
Risk Factors
Zacks Research downgraded Cardinal Health to hold in late June.
High P/E ratio of 34.95 suggests priced-in future growth.
Bullish Signals
Assetmark Inc. significantly increased its stake in Cardinal Health by 35.4% in the first quarter, indicating institutional confidence.
Multiple new institutional investors entered positions in Q4 and Q1, including Aventura Private Wealth LLC and Indiana Trust & Investment Management Co.
Morgan Stanley raised its price target to $255.00 and reaffirmed an 'overweight' rating on the stock.
Bank of America increased its price objective to $260.00 and maintained a 'buy' rating.
Citigroup reiterated its 'buy' rating on Cardinal Health shares.
William Blair initiated coverage with an 'outperform' rating, adding to the bullish analyst consensus.
The company increased its quarterly dividend from $0.51 to $0.5158, reflecting a commitment to shareholder returns.
Fifteen analysts rate the stock as a Buy compared to only three Hold ratings.
Risk Factors
Zacks Research downgraded Cardinal Health from a 'strong-buy' to a 'hold' rating in late June.
The stock has a high P/E ratio of 34.95, which may suggest the market is pricing in significant future growth.
Bleakley Financial Group LLC acquired a new position in Cardinal Health, Inc. (NYSE:CAH) during the first quarter, purchasing 20,619 shares valued at approximately $4.36 million. Other institutional investors, including Aventura Private Wealth and University of Texas Investment Management, also established or increased stakes, while Jones Financial Companies significantly lifted its position by 198.3%. Institutional ownership remains high at 87.17%, indicating continued interest from major funds.
Analyst sentiment regarding Cardinal Health is mixed but generally positive, with a consensus rating of 'Moderate Buy' and an average price target of $249.13. While Evercore and Wells Fargo recently lowered their price targets to $240 and $245 respectively, TD Cowen raised its objective to $275 with a 'buy' rating, and Citigroup reissued a 'buy'. The stock currently trades at a PE ratio of 34.37 with a market capitalization of $52.64 billion.
Financially, Cardinal Health reported Q1 earnings of $3.17 per share, beating analyst estimates of $2.79, though revenue of $60.94 billion missed expectations at $62.10 billion. Revenue grew 11% year-over-year to $60.94 billion. The company recently increased its quarterly dividend to $0.5158 per share, representing a yield of 0.9% and a payout ratio of 31.50%. FY 2026 guidance stands between $10.70 and $10.80 EPS.
📈 Bleakley Financial Group acquired $4.36M position in Q1.
📉 Jones Financial lifted position by 198.3% to $27,000 value.
💰 Revenue hit $60.94B (up 11%) but missed estimates.
📈 EPS of $3.17 beat analyst consensus of $2.79.
🎯 Consensus price target stands at $249.13 with 'buy' ratings.
📈 Bleakley Financial Group LLC acquired a new position in Cardinal Health valued at approximately $4.36 million during the first quarter.
📉 Jones Financial Companies Lllp lifted its position by 198.3%, now holding 21,112 shares valued at $27,000.
📊 Cardinal Health reported Q1 EPS of $3.17, surpassing analyst consensus estimates of $2.79.
💰 The company generated revenue of $60.94 billion for the quarter, representing an 11% year-over-year increase.
📉 Revenue missed analyst expectations of $62.10 billion by approximately $1.16 billion.
📈 TD Cowen raised its price target to $275 and maintained a 'buy' rating on the stock.
📉 Evercore decreased its price target from $260 to $240 while maintaining an 'outperform' rating.
💵 Cardinal Health increased its quarterly dividend to $0.5158, resulting in an annualized yield of 0.9%.
🎯 The consensus analyst price target for the stock is currently set at $249.13.
📉 Wells Fargo lowered its price target to $245 but retained an 'overweight' rating.
🏢 Cardinal Health operates as a major provider of supply chain and distribution services for the healthcare sector.
📈 Institutional investors own 87.17% of the company's outstanding stock.
Bullish Signals
EPS of $3.17 beat estimates by $0.38.
Revenue grew 11% YoY to $60.94 billion.
TD Cowen raised price target to $275.
Citigroup reissued a 'buy' rating.
Quarterly dividend increased to $0.5158.
Jones Financial stake surged 198.3%.
Risk Factors
Q1 revenue of $60.94B missed consensus of $62.10B.
Evercore cut price target from $260.00 to $240.00.
Wells Fargo lowered target from $256.00 to $245.00.
Negative return on equity of 92.61% reported.
Bullish Signals
Cardinal Health reported Q1 earnings per share of $3.17, which beat analyst consensus estimates of $2.79 by $0.38.
The company achieved a significant 11% year-over-year revenue growth, reaching $60.94 billion for the quarter.
TD Cowen increased its price objective to $275 and issued a 'buy' rating on the stock.
Citigroup reissued a 'buy' rating on Cardinal Health shares in a recent research report.
The company recently increased its quarterly dividend from $0.51 to $0.5158 per share.
Jones Financial Companies Lllp significantly increased its stake by 198.3% during the first quarter.
Bleakley Financial Group LLC established a new position valued at approximately $4.36 million in the company.
Risk Factors
Cardinal Health's Q1 revenue of $60.94 billion missed analyst consensus estimates of $62.10 billion.
Evercore decreased its price target on Cardinal Health from $260.00 to $240.00 in a recent report.
Wells Fargo & Company lowered its price target on the stock from $256.00 to $245.00.
The company reported a negative return on equity of 92.61% for the quarter.
Cardinal Health (NYSE:CAH) received a 'strong-buy' rating upgrade from Wall Street Zen analysts, contrasting with a recent downgrade to 'hold' by Zacks Research. The stock maintains a consensus 'Moderate Buy' rating among fifteen analysts with a price target of $247.80, though Wells Fargo recently lowered its objective to $245.00 while TD Cowen raised theirs to $255.00.
The company reported Q1 earnings of $3.17 per share, beating the consensus estimate of $2.79 by $0.38. Revenue reached $60.94 billion, representing an 11.0% year-over-year increase, though it fell slightly short of analyst expectations at $62.10 billion. The firm posted a net margin of 0.62% and issued FY 2026 guidance ranging between $10.70 and $10.80 EPS.
Institutional ownership remains high at 87.17%, with several major investors increasing their stakes in the first or second quarter. Integrated Wealth Concepts LLC boosted its position by 6.9%, while Jones Financial Companies Lllp grew its stake significantly by 198.3%. Other notable increases came from Cerity Partners LLC and Nebula Research & Development LLC, signaling continued institutional interest despite mixed analyst ratings.
📈 Wall Street Zen upgraded stock to 'strong-buy' rating on Saturday.
📉 Zacks Research downgraded stock from 'strong-buy' to 'hold' on Friday.
💰 Q1 earnings hit $3.17/share, beating estimates by $0.38.
📊 Revenue reached $60.94 billion, an 11.0% year-over-year increase.
🎯 FY 2026 EPS forecast is $10.70-$10.80 with $247.80 price target.
📈 Wall Street Zen upgraded Cardinal Health to a 'strong-buy' rating in a new research report issued on Saturday.
📉 Zacks Research downgraded the stock from 'strong-buy' to 'hold' in a report released on Friday, June 12th.
💰 The company reported Q1 earnings of $3.17 per share, surpassing the consensus estimate of $2.79 by $0.38.
📊 Revenue for the quarter totaled $60.94 billion, marking an 11.0% increase compared to the previous year.
🎯 Analysts forecast FY 2026 EPS between $10.70 and $10.80, with a consensus price target of $247.80.
🏦 Wells Fargo lowered its price objective to $245.00 while TD Cowen raised theirs to $255.00 in recent notes.
📉 The firm reported a negative return on equity of 92.61% and a net margin of 0.62% for the quarter.
🏢 Institutional ownership stands at 87.17%, with hedge funds and other investors holding significant positions.
🚀 Jones Financial Companies Lllp increased its stake by 198.3% in the first quarter, now owning 21,112 shares.
📦 Cardinal Health operates as a major provider of supply chain and distribution services for the healthcare sector.
Bullish Signals
Wall Street Zen upgraded Cardinal Health to 'strong-buy' rating.
Beat quarterly earnings with $3.17 EPS vs $2.79 consensus.
Revenue grew 11.0% YoY to reach $60.94 billion.
Institutional holdings surged, including 198.3% increase by Jones Financial.
Consensus price target of $247.80 suggests continued upside.
Risk Factors
Zacks downgraded stock to 'hold' rating.
Revenue of $60.94B missed $62.10B expectations.
Negative return on equity of 92.61%.
Wells Fargo lowered price objective to $245.
Bullish Signals
Wall Street Zen upgraded Cardinal Health to a 'strong-buy' rating, indicating renewed analyst confidence in the company's prospects.
The company beat quarterly earnings expectations with $3.17 EPS compared to the consensus of $2.79, demonstrating operational strength.
Revenue grew by 11.0% year-over-year to reach $60.94 billion, reflecting strong demand for its healthcare distribution services.
Multiple institutional investors increased their holdings, including a massive 198.3% stake increase by Jones Financial Companies Lllp.
The consensus price target of $247.80 suggests continued market interest and potential upside from current levels.
Risk Factors
Zacks Research downgraded the stock to a 'hold' rating, creating conflicting analyst sentiment that may complicate investment decisions.
Revenue of $60.94 billion missed analyst expectations of $62.10 billion, indicating some pressure on top-line growth relative to forecasts.
The company reported a negative return on equity of 92.61%, which could signal underlying capital efficiency issues or leverage concerns.
Wells Fargo lowered its price objective from $256.00 to $245.00, reflecting bearish sentiment among some major financial institutions.
IFM Investors Pty Ltd increased its stake in Cardinal Health, Inc. (NYSE:CAH) by 14.6% during the first quarter, purchasing an additional 5,489 shares to hold a total of 42,962 shares valued at approximately $9.08 million. Several other institutional investors also adjusted their positions, with Jones Financial Companies Lllp significantly increasing its holding by 198.3% and multiple firms establishing new stakes in the fourth quarter.
Analyst sentiment regarding Cardinal Health remains mixed but generally positive, with TD Cowen raising its price target to $255 and reaffirming a 'buy' rating, while JPMorgan Chase lowered its target to $215 with a 'neutral' rating. The consensus among 18 analysts is a 'Moderate Buy' with an average price target of $247.80, reflecting ongoing debate over the company's valuation and growth prospects.
Financially, Cardinal Health reported strong quarterly earnings of $3.17 per share, beating analyst estimates by $0.38, though revenue of $60.94 billion missed expectations of $62.10 billion. The company raised its full-year 2026 guidance to an EPS range of $10.70-$10.80 and increased its quarterly dividend to $0.5158, signaling confidence in future cash flow generation despite the recent revenue miss.
The healthcare distributor operates with a market capitalization of $55.93 billion and maintains a P/E ratio of 36.51. With institutional ownership at 87.17%, the stock is heavily held by professional investors who are closely monitoring its ability to sustain growth in supply chain services amidst competitive pressures and margin constraints.
📈 IFM Investors added 5,489 shares for a $9.08 million holding.
📉 Jones Financial surged position by 198.3% to own 21,112 shares.
💰 Q1 EPS hit $3.17, beating estimates by $0.38.
📉 Revenue reached $60.94 billion, missing the $62.10 billion target.
🚀 FY 2026 EPS guidance raised to $10.70-$10.80 range.
📈 IFM Investors Pty Ltd increased its Cardinal Health stake by 14.6% in Q1, adding 5,489 shares for a total holding of 42,962 shares valued at $9.08 million.
📉 Jones Financial Companies Lllp surged its position by 198.3%, acquiring an additional 14,034 shares to own 21,112 shares worth $27,000.
💰 Cardinal Health reported Q1 EPS of $3.17, surpassing analyst consensus estimates of $2.79 by $0.38.
📉 Revenue for the quarter reached $60.94 billion, falling short of the $62.10 billion expected by analysts.
🚀 The company raised its FY 2026 EPS guidance to a range of $10.70-$10.80, exceeding the average analyst expectation of $10.76.
💵 Cardinal Health increased its quarterly dividend to $0.5158, representing a yield of 0.9% and an annualized payout of $2.06.
📊 TD Cowen raised its price target to $255 with a 'buy' rating, while JPMorgan Chase lowered its target to $215 with a 'neutral' rating.
🏢 Institutional ownership stands at 87.17%, indicating strong interest from hedge funds and asset managers.
📈 The stock trades at a P/E ratio of 36.51 with a market capitalization of $55.93 billion.
📉 Revenue growth slowed to 11.0% year-over-year, though this remains robust compared to the prior year's performance.
Cardinal Health (NYSE:CAH) shares reached a new 52-week high, trading as high as $240.93 with a volume of over 1.9 million shares. The stock recently closed at $237.92, reflecting continued investor interest despite mixed analyst sentiment regarding the company's recent performance and future outlook.
In its latest quarterly earnings report released on April 30th, Cardinal Health reported EPS of $3.17, significantly beating the consensus estimate of $2.79. However, revenue came in at $60.94 billion, falling short of analyst expectations of $62.10 billion. The company achieved an 11% year-over-year revenue increase but posted a net margin of only 0.62% and a negative return on equity of 92.61%.
Looking ahead, Cardinal Health has set full-year 2026 guidance between $10.70 and $10.80 per share, while analysts currently expect $10.76 EPS for the fiscal year. The company also declared a quarterly dividend of $0.5158 per share, payable on July 15th to shareholders of record on July 1st, representing an increase from the previous quarter's payout and a yield of approximately 0.9%.
Institutional ownership remains strong at 87.17%, with notable activity from major funds including Wellington Management Group, which lifted its stake by 153.2%, and Marshall Wace LLP, which increased its position by over 1,300%. These institutional moves suggest continued confidence in the company's long-term positioning within the healthcare distribution sector.
📈 Stock hit new 52-week high of $240.93 with strong volume.
💰 Q1 EPS beat estimates at $3.17 vs consensus of $2.79.
📉 Revenue missed forecasts but grew 11% year-over-year to $60.94B.
💸 Net margin low at 0.62% with negative return on equity.
🎯 FY 2026 guidance set between $10.70 and $10.80 EPS.
📈 Cardinal Health stock hit a new 52-week high of $240.93 with significant trading volume.
💰 Q1 EPS beat estimates at $3.17 versus the consensus of $2.79.
📉 Revenue missed analyst expectations, coming in at $60.94 billion against a forecast of $62.10 billion.
📈 Revenue grew 11% year-over-year to reach $60.94 billion for the quarter.
💸 Net margin was low at 0.62% with a negative return on equity of 92.61%.
🎯 FY 2026 guidance set between $10.70 and $10.80 EPS by management.
📊 Analysts expect full-year 2026 EPS of $10.76, slightly above company guidance.
💵 Quarterly dividend increased to $0.5158 per share with a yield of 0.9%.
🏦 Institutional ownership stands at 87.17% of the company's total shares.
📈 Wellington Management Group increased its stake by 153.2% in the third quarter.
🚀 Marshall Wace LLP grew its position by 1,328.1% during the fourth quarter.
🏥 Cardinal Health operates as a major provider of supply chain and distribution services for healthcare.
📦 Core business includes wholesale distribution of pharmaceuticals and medical-surgical products.
🌍 The company serves hospitals, pharmacies, physician offices, and clinical laboratories globally.
📅 Earnings data was last announced on Thursday, April 30th.
Bullish Signals
Stock hit new 52-week high of $240.93.
EPS of $3.17 beat consensus by $0.38.
Revenue grew 11% year-over-year to $60.94 billion.
Institutional ownership remains robust at 87.17%.
Morgan Stanley raised price target to $255.00.
Risk Factors
Revenue missed expectations by over $1 billion.
Net margin extremely low at just 0.62%.
Return on equity negative at -92.61%.
Zacks Research lowered rating from strong-buy to hold.
Weiss Ratings cut stock rating from buy (b+) to buy (b).
Bullish Signals
Stock price reached a new 52-week high of $240.93, indicating strong market momentum.
Reported EPS of $3.17 significantly beat the consensus estimate of $2.79 by $0.38.
Cardinal Health (CAH) shares rose 7.3% following the company's latest earnings report, which featured an earnings per share (EPS) beat despite a slight miss in total revenue. The stock's performance is being bolstered by positive developments in its neonatal intensive care respiratory devices segment, a market projected to expand significantly to approximately US$5.70 billion by 2035.
Analysts and investors view the combination of consistent earnings outperformance and exposure to this high-growth medical device niche as reinforcing Cardinal Health's broader healthcare distribution platform. While the EPS beat supports short-term resilience, the company continues to face long-term headwinds from government pricing scrutiny and tariffs that could pressure margins.
The article highlights Cardinal Health's ongoing share repurchases under a multi-year buyback plan as a key near-term catalyst for shareholders. However, fair value estimates vary widely among analysts, ranging from US$190 to US$466 per share, reflecting differing views on the company's ability to sustain earnings power against regulatory and competitive risks.
📈 Shares jumped 7.3% on EPS beat despite revenue miss.
💊 Neonatal respiratory market projected to reach $5.7B by 2035.
🛡️ Consistent earnings outperformance reinforces investor confidence in core platform.
🔄 Ongoing buybacks support shareholder returns under multi-year plan.
⚠️ Long-term margin pressure remains due to pricing scrutiny and tariffs.
📈 Cardinal Health shares jumped 7.3% after reporting an EPS beat despite a slight revenue miss.
💊 The neonatal respiratory devices market is projected to reach US$5.70 billion by 2035, providing a growth tailwind.
🛡️ Consistent earnings outperformance reinforces investor confidence in the company's core distribution platform.
🔄 Ongoing share repurchases under a multi-year buyback plan support shareholder returns.
⚠️ Long-term margin pressure remains a concern due to government pricing scrutiny and tariffs.
📊 Analyst fair value estimates for CAH vary widely between US$190 and US$466 per share.
Bullish Signals
EPS beat demonstrates operational resilience.
NICU respiratory market grows to $5.70B by 2035.
Share repurchase plan returns capital.
Risk Factors
Revenue missed targets, signaling core distribution headwinds.
Analyst fair value estimates range widely from $190 to $466.
Bullish Signals
Cardinal Health delivered an earnings per share (EPS) beat in its latest quarterly report, demonstrating operational resilience.
The company is well-positioned in the expanding neonatal intensive care respiratory devices market, which is expected to grow to US$5.70 billion by 2035.
Continued execution of a multi-year share repurchase plan signals management's commitment to returning capital to shareholders.
Risk Factors
The company reported a slight miss in total revenue, indicating potential headwinds in its core distribution business.
Significant divergence in analyst fair value estimates (ranging from US$190 to US$466) suggests uncertainty regarding the stock's long-term valuation.
Cardinal Health (CAH) recently reported an 11% year-over-year revenue increase and raised its fiscal 2026 non-GAAP earnings per share (EPS) guidance. These developments have coincided with stronger demand for high-margin specialty drugs, driving renewed investor attention to the stock.
The positive momentum is reflected in strong price action, with Cardinal Health posting a 30-day share price return of 16.66% and a one-year total shareholder return of 39.64%. Analysts maintain a consensus price target of $245.27 against a recent closing price of $227.72, suggesting the stock could be undervalued by approximately 7.2% based on specific growth and margin assumptions.
However, valuation concerns persist as the company trades at a P/E ratio of 34.3x, which is significantly higher than the US healthcare industry average of 23.2x and peer group average of 25.9x. While analysts see upside potential ranging from $215 to $275 per share, risks include tighter regulation, pricing scrutiny, and the potential loss of major customer contracts that could challenge future growth.
The article concludes by weighing the optimism around steady revenue gains and modest margin improvement against the risk of a market correction if sentiment cools. Investors are advised to consider whether the current premium multiple is justified given the company's exposure to regulatory headwinds and competitive pressures in the specialty drug sector.
📈 Revenue rose 11% YoY with raised fiscal 2026 EPS guidance.
💰 Stock gained 16.66% in 30 days and 39.64% total return last year.
🎯 Analyst consensus target is $245.27, implying 7.2% upside from current price.
⚖️ P/E ratio of 34.3x exceeds US healthcare average of 23.2x.
⚠️ Risks include tighter regulation and potential loss of major customer contracts.
📈 Cardinal Health reported an 11% year-over-year revenue increase alongside a raise in fiscal 2026 non-GAAP EPS guidance.
💰 The stock has gained 16.66% over the past 30 days and delivered a 39.64% total shareholder return over the last year.
🎯 Analyst consensus price target is $245.27, implying a potential 7.2% upside from the recent close of $227.72.
⚖️ The company trades at a P/E ratio of 34.3x, which exceeds the US healthcare industry average of 23.2x and peer average of 25.9x.
🛡️ Analysts have identified a bullish price target of $275.00 and a bearish target of $215.00, highlighting valuation disagreement.
⚠️ Key risks include tighter regulation, increased pricing scrutiny, and the potential loss of major customer contracts.
📉 If market sentiment cools, the high P/E multiple could lead to price adjustments rather than earnings compression.
💊 Stronger demand for high-margin specialty drugs is cited as a key driver supporting recent stock momentum.
Bullish Signals
11% year-over-year revenue increase.
Raised fiscal 2026 non-GAAP EPS guidance.
39.64% one-year total shareholder return.
$245.27 fair value suggests discount.
High-margin specialty drug demand tailwind.
Risk Factors
P/E ratio of 34.3x exceeds industry average of 23.2x.
Tighter regulation threatens future revenue growth and margins.
Loss of major contracts impacts revenue stability.
Analyst price targets range from $215.00 to $275.00.
Bullish Signals
Cardinal Health achieved an 11% year-over-year revenue increase, demonstrating solid top-line growth.
The company raised its fiscal 2026 non-GAAP EPS guidance, signaling confidence in future profitability.
Strong price action with a 30-day return of 16.66% and a one-year total shareholder return of 39.64% indicates building momentum.
Analyst consensus fair value of $245.27 suggests the stock is currently trading at a discount relative to growth expectations.
Increased demand for high-margin specialty drugs provides a favorable tailwind for the company's core business segments.
Risk Factors
The current P/E ratio of 34.3x is significantly higher than the US healthcare industry average of 23.2x and peer average of 25.9x, creating valuation risk.
Tighter regulation and increased pricing scrutiny pose potential threats to future revenue growth and margins.
The loss of major customer contracts could materially impact the company's revenue stability and growth trajectory.
Analyst disagreement on price targets, ranging from $215.00 to $275.00, indicates uncertainty regarding the stock's long-term valuation.
Your Privacy
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Measure audience engagement and site statistics to understand how our services are used (Google Analytics)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
You can accept all cookies or configure your preferences. You can change them at any time via the "Manage Cookies" link in the footer.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Analytics cookies
Help us understand how visitors interact with our website using Google Analytics. These cookies collect information anonymously.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
